INTRODUCTION
============

Flap necrosis is a serious complication following reconstructive surgery for soft tissue coverage, with treatment at times requiring a return to the operating room or prolonged wound care.^[@R1]^ Inadequate neovascularization and insufficient production of pro-angiogenic mediators are likely culprits for the poor healing. Injection of adipose-derived mesenchymal stem cells (ADSCs) into skin flaps has been shown by several investigators to increase flap survival and angiogenesis in various skin flap models.^[@R2]--[@R5]^ Recently, extracellular vesicles (EVs) released from ADSCs as a cell-free alternative were also found to improve flap viability after ischemia--reperfusion injury.^[@R6]^ Bai et al determined that exposure of parent ADSCs to oxidative stress via a low concentration of hydrogen peroxide (H~2~O~2~) enhanced the angiogenic effects of the EVs, but the mechanisms by which this occurs remain unclear.^[@R7]^

The beneficial effects of mesenchymal stem cell (MSC)-based therapies have been proposed to be mediated predominantly by paracrine activity, to include soluble factors and EVs secreted from MSCs.^[@R8]--[@R11]^ EVs are composed of different types of vesicles including exosomes (40--200 nm), which are of endosomal origin, and microvesicles (150--1,000 nm), which directly bud from the cell membrane.^[@R8]--[@R11]^ Because current isolation methods cannot physically separate exosomes from small microvesicles, the term "EVs" in this manuscript refers to vesicles in the size range of exosomes. MSCs have been shown to release EVs that can selectively package and transfer proteins, nucleic acids including microRNAs (miRNAs), and lipids to injured tissues which are capable of modulating gene expression and the biological activity of recipient cells.^[@R8]--[@R11]^ MiRNAs are an important class of highly conserved, small (\~22 nucleotide), nonprotein-coding RNAs that regulate gene expression via degradation or translational repression of their targeted mRNA transcripts.^[@R12]^ They are significant modulators of numerous fundamental physiological and cellular processes including angiogenesis, and their dysregulation is implicated in several diseases.^[@R12],[@R13]^

Results from several studies indicate that angiogenesis-related miRNAs and proteins are the main components in EVs to exert their pro-angiogenic function (reviewed in Bian et al)^[@R14]^ ADSC-EVs are enriched with specific protein and miRNA cargo molecules that simultaneously activate their related signal pathway to regulate the expression of angiogenic factors in endothelial cells.^[@R13]--[@R17]^ EV cargo can change in response to different microenvironments, for example, EVs secreted under hypoxic conditions have been shown to contain increased expression of platelet-derived growth factor, epidermal-derived growth factor, fibroblast growth factor, and nuclear factor kappaB signaling pathway proteins and pro-angiogenic miRNAs including miR-126, miR-130a, and miR-210.^[@R18],[@R19]^

The identity of which components of the EV proteome and miRNome responsible for the increased skin flap viability observed after H~2~O~2~ preconditioning of parent ADSCs has not been determined.^[@R7]^ Therefore, the aims of this study were to (1) use unbiased proteomics and next-generation sequencing approaches to comprehensively characterize the protein and miRNA content of EVs released from human ADSCs under normal culture conditions (control ADSC-EVs) and from ADSCs preconditioned with H~2~O~2~ (H~2~O~2~ ADSC-EVs) and (2) determine whether H~2~O~2~-induced changes in EV composition can increase viability of random pattern skin flaps in an established mouse model.

MATERIALS AND METHODS
=====================

Cell Culture
------------

Human ADSCs (ATCC PCS-500-011; American Type Culture Collection, Manassas, VA) were expanded under standard culture conditions in a complete medium \[Dulbecco's Modified Eagle's Medium (DMEM) High Glucose (ThermoFisher Scientific, Waltham, MA)\] containing 10% MSC-qualified fetal bovine serum (MilliporeSigma, Burlington, MA)/1×GlutaMAX/1×penicillin--streptomycin (ThermoFisher Scientific). These cells have been verified by ATCC to be multipotent, capable of differentiating into adipocytes, osteoblasts, and chondrocytes and analyzed using different cluster of differentiation (CD) markers to confirm that they meet MSC criteria as defined by the International Society for Cellular Therapy.^[@R20]^ For isolation of control ADSC-EVs and H~2~O~2~ ADSC-EVs, culture medium was replaced with DMEM High Glucose without Phenol Red/1×GlutaMAX (ThermoFisher Scientific) containing 5% exosome-depleted fetal bovine serum (Exo-FBS; System Biosciences \[SBI\], Palo Alto, CA) ± 50 µM H~2~O~2~ when cells (at passage 5--8) reached 60%--80% confluence. Cells were cultured for an additional 65 hours, and then the medium was collected and stored at --80°C until EV isolation.

Proteomic Analysis
------------------

Proteomic analysis of control ADSC-EVs and H~2~O~2~ ADSC-EVs was performed by SBI utilizing SBI's ExoMS Total Exosome Protein Profiling Service. Briefly, EVs were isolated using an affinity purification strategy to remove free protein. Isolated EVs were lysed in a gel-loading buffer, and the protein concentration was determined by Qubit protein assay (ThermoFisher Scientific). EV proteins (10 µg) were processed for gel-based extraction and trypsinization to generate peptidic libraries for liquid chromatography/mass spectrometry matrix-assisted laser desorption/ionization-time-of-flight and electrospray ionization-time-of-flight mass spectrometry. Half of the gel digest was analyzed by nano-LC-MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive mass spectrometer. Peptides were loaded on a trapping column and eluted over a 75-µm analytical column at 350 nL/min; both columns were packed with Luna C18 resin (Phenomenex, Torrance, CA). The mass spectrometer was operated in data-dependent mode, with the Orbitrap operating at 70,000 full width at half maximum and 17,500 full width at half maximum for MS and MS/MS, respectively. The 15 most abundant ions were selected for MS/MS.

Peptide signatures were mapped to a database of known protein sequences (SwissProt Human) using Mascot (Matrix Science, Boston, MA). Mascot DAT files were parsed into Scaffold Proteome Software (Portland, OR) for validation, filtering, and to create a nonredundant list per sample. Data were filtered using 1% protein and peptide false discovery rate and requiring at least 2 unique peptides per protein. Normalized spectral abundance factor (NSAF) values were calculated based on the equation: NSAF = (SpC/MW)/Σ(SpC/MW)~N~, where SpC is the spectral counts, MW is the protein molecular weight in kDa, and N is the total number of proteins. NSAF values were used to approximate the relative abundance of proteins within a given sample, and relative abundance of a given protein between samples. Functional Gene Ontology (GO) enrichment analysis of identified proteins was performed using the Functional Annotation Clustering Tool in the Database for Annotation, Visualization and Integrated Discovery (DAVID Bioinformatics Resource 6.8) using default settings.^[@R21],[@R22]^

RNA Sequencing Analysis
-----------------------

Next-generation sequencing (NGS) of control ADSC-EVs and H~2~O~2~ ADSC-EVs was performed by SBI utilizing SBI's Exosome RNA NGS Service. Briefly, EVs were isolated using SBI's ExoQuick precipitation method, and RNA was extracted using the SeraMir Exosome RNA Purification Column Kit (SBI). Measurement of small RNA concentration was determined using a Bioanalyzer 2100 instrument with the Agilent Small RNA Kit (Agilent Technologies, Santa Clara, CA). Small RNA libraries were constructed with the CleanTag Small RNA Library Preparation Kit (TriLink Biotechnologies, San Diego, CA). The final purified library was quantified with the High Sensitivity DNA Kit (Agilent Technologies). The libraries were pooled, and the 140--300-bp region was size selected on an 8% TBE (tris-borate-ethylenediaminetetraacetic acid) gel. The size-selected library was quantified with the High Sensitivity DNA 1000 Screen Tape Kit (Agilent Technologies) and the TailorMix HT1 qPCR Assay (SeqMatic, Fremont, CA), followed by a NextSeq High Output single-end sequencing run at SR75 using NextSeq 500/550 High Output v2 Kit (Illumina, San Diego, CA) at a depth of 5--15 million reads per sample. Data analysis was conducted using the Banana Slug Exosome RNA-seq Analysis platform using the human reference GRCh37/hg19 assembly (UCSC Genome Bioinformatics, Santa Cruz, CA). Differentially expressed miRNAs were identified using the DESeq package and reported as fold change \>2 with significance considered at *P* \< 0.01 (adjusted for multiple comparisons).

To determine the biological significance of differentially expressed EV miRNAs, TargetScan Release 7.2 was used to generate a list of predicted miRNA targets.^[@R23]^ A cutoff of ≤ --0.3 cumulative weighted context ++ score was used to exclude weak predictions. GO enrichment analysis of predicted target genes was performed using DAVID.^[@R21],[@R22]^

EV Isolation (Animal Experiments)
---------------------------------

Cell debris was removed by centrifugation at 300*g* for 10 minutes and then 3,000*g* for 30 minutes. Medium was passed through a 0.22-µm filter and concentrated using a 10-kDa molecular weight Amicon Ultra-15 Centrifugal Filter (MilliporeSigma). EVs were isolated from the supernatants using ExoQuick-TC Ultra precipitation solution (SBI) according to the manufacturer's protocol and aliquots stored at --80°C before use. Aliquots of EVs were diluted in phosphate-buffered saline, and EV size and concentration were determined using nanoparticle tracking analysis by means of a NanoSight NS300 (Malvern Panalytical, Malvern, UK). Nanoparticle tracking analysis estimated the peak size of ADSC-EVs as 126 ± 8 nm and H~2~O~2~ ADSC-EVs as 150 ± 29 nm (n = 3 batches). Total protein concentration of EVs was determined by Qubit protein assay (ThermoFisher Scientific).

Random Pattern Skin Flap Model and In Vivo Study Design
-------------------------------------------------------

The efficacy of control ADSC-EVs and H~2~O~2~ ADSC-EVs to improve viability of random pattern skin flaps was examined using an established mouse model.^[@R2],[@R24]^ The study protocol was approved by the Institutional Animal Care and Use Committee at Tripler Army Medical Center. Investigators complied with the policies as prescribed in the US Department of Agriculture Animal Welfare Act and the National Research Council's *Guide for the Care and Use of Laboratory Animals*. Facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.

A total of 14 male BALB/c mice (9--12 weeks old, Charles River Laboratories, Wilmington, MA) were used. Cranially based, dorsal 4 cm × 2 cm random pattern skin flaps beginning 1 cm caudal to the occipital neckline were raised in mice deeply anesthetized under isoflurane inhalation. To help create a reliable ischemic gradient from the flap base, axial vessels (if present) were crushed and a medical grade silicone sheet (approximately 0.13 mm thick) was inserted to separate the flap and avoid neovascularization from the bed. The flap was sutured in place with 4-0 nylon and left without a dressing. Animals then received intradermal injections (300 µL total volume) of control ADSC-EVs (3 × 10^10^ particles; n = 4 mice), H~2~O~2~ ADSC-EVs (3 × 10^10^ particles; n = 5 mice), or vehicle (n = 5 mice) at approximately 10 points throughout the proximal, middle, and distal regions of the flap. Although H~2~O~2~ stimulation increased the number of EVs 2.5 ± 0.4-fold (n = 3 batches), particle number was adjusted to inject equal numbers of EVs per group. Buprenorphine was administered subcutaneously (0.05 mg/kg) during surgery and orally (0.4 mg/kg mixed in 2 g/kg of hazelnut spread) every 12 hours for 2 days.

On day 7, mice were euthanized and flaps were photographed with a ruler in the field of view to enable calibration. Flap survival was determined grossly based on color, texture, and overall appearance. Sizes of viable and necrotic areas were measured using digital image analysis by 2 observers (ImageJ software, National Institutes of Health). A tissue biopsy (1 cm^2^) was taken 3 mm proximal to the necrotic margin on the viable side and processed for histology.

Histologic Analysis
-------------------

Tissues were fixed in formalin and embedded in paraffin, and serial sections (5 µm) were stained with hematoxylin--eosin. The number of capillaries per high-power field (400× magnification) were counted in a minimum of 10 fields per section by 2 blinded investigators and averaged.

Statistical Analysis
--------------------

Data are reported as mean ± standard error of the mean. GO enrichment analysis in DAVID used a modified Fisher's exact test to determine whether genes were enriched in the annotation categories, and enrichment statistics were adjusted for multiple hypothesis testing by the Benjamini correction. All other statistical analyses were performed using SigmaPlot 11.2 software (Systat Software, San Jose, CA) with *P* \< 0.05 considered significant. Comparisons among groups (viability measurements and capillary density) were made using 1-way analysis of variance (ANOVA) followed by multiple comparison testing (Holm-Sidak method) to assess differences between individual pairs of means among the groups.

RESULTS
=======

Protein Content of ADSC-EVs and H~2~O~2~ ADSC-EVs
-------------------------------------------------

To analyze the protein content of EVs produced by ADSCs with or without H~2~O~2~ stimulation, MS analysis of the proteome of control ADSC-EVs and H~2~O~2~ ADSC-EVs was performed. As demonstrated in the Venn diagram (Fig. [1](#F1){ref-type="fig"}), 68 proteins were common to both groups, 40 proteins were found only in control ADSC-EVs, and 18 proteins were found only in H~2~O~2~ ADSC-EVs. Functional GO enrichment analysis using DAVID software revealed that approximately 87% of identified proteins in both groups were associated with the GO term extracellular exosome (Benjamini *P* value control ADSC-EVs = 2.64 × 10^--55^, H~2~O~2~ ADSC-EVs = 1.47 × 10^--45^). Altogether, 40%--50% of identified proteins were classified as secreted proteins. The most highly enriched biological processes common to both groups were extracellular matrix organization and keratinocyte differentiation (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Enriched GO biological processes unique to control ADSC-EVs included innate immune response and phagocytosis (Table [3](#T3){ref-type="table"}). Interestingly, the major enriched GO term unique to H~2~O~2~ ADSC-EVs that remained significant after the adjustment for multiple hypothesis testing using the conservative Benjamini correction was constitutive photomorphogenesis 9 (COP9) signalosome, which directs the production of vascular endothelial growth factor (Table [4](#T4){ref-type="table"}).^[@R25]^

###### 

Functional Annotation Clustering Analysis of Control ADSC-EV Proteome

  Term                                                                    Count   \%     *P*        Benjamini *P*
  ----------------------------------------------------------------------- ------- ------ ---------- ---------------
  Functional annotation cluster 1 enrichment score: 16.76                                           
   GO:0005615 extracellular space                                         58      54.7   6.73E-37   7.14E-35
   GO:0005576 extracellular region                                        52      49.1   2.05E-26   1.09E-24
   UP_KEYWORDS secreted                                                   53      50     8.49E-26   1.96E-23
   UP_KEYWORDS signal                                                     51      48.1   2.62E-10   2.01E-08
   UP_KEYWORDS glycoprotein                                               50      47.2   2.14E-08   8.23E-07
  Functional annotation cluster 2 enrichment score: 6.93                                            
   GO:0018149 peptide cross-linking                                       10      9.4    1.91E-11   5.65E-09
   GO:0030216 keratinocyte differentiation                                11      10.4   3.63E-11   8.04E-09
   GO:0031424 keratinization                                              7       6.6    4.85E-07   7.16E-05
   GO:0008544 epidermis development                                       8       7.5    9.47E-07   1.20E-04
  Functional annotation cluster 3 enrichment score: 5.55                                            
   UP_KEYWORDS extracellular matrix                                       13      12.3   8.11E-09   4.68E-07
   GO:0030198 extracellular matrix organization                           12      11.3   3.59E-08   6.35E-06
   GO:0005518 collagen binding                                            5       4.7    4.73E-04   0.0083
  Functional annotation cluster 4 enrichment score: 5.49                                            
   GO:0010951 negative regulation of endopeptidase activity               13      12.3   1.11E-11   4.93E-09
   GO:0004867 serine-type endopeptidase inhibitor activity                9       8.5    1.25E-07   1.44E-05
   UP_KEYWORDS protease inhibitor                                         9       8.5    2.37E-07   6.83E-06
  Functional annotation cluster 5 enrichment score: 4.54                                            
   GO:0044267 cellular protein metabolic process                          8       7.5    8.56E-06   8.42E-04
  Functional annotation cluster 6 enrichment score: 4.4                                             
   GO:0002576 platelet degranulation                                      8       7.5    3.47E-06   3.84E-04
   GO:0031093 platelet alpha granule lumen                                6       5.7    1.60E-05   2.60E-04
   GO:0005577 fibrinogen complex                                          3       2.8    0.0011     0.0128
  Functional annotation cluster 7 enrichment score: 3.87                                            
   GO:0007155 cell adhesion                                               12      11.3   1.28E-04   0.0075
  Functional annotation cluster 8 enrichment score: 3.54                                            
   UP_KEYWORDS antimicrobial                                              7       6.6    1.92E-05   2.33E-04
   GO:0050832 defense response to fungus                                  4       3.8    6.06E-04   0.0221
   GO:0042742 defense response to bacterium                               6       5.7    0.0021     0.0543
  Functional annotation cluster 9 enrichment score: 3.15                                            
   GO:0016209 antioxidant activity                                        5       4.7    5.65E-06   2.60E-04
   GO:0000302 response to reactive oxygen species                         5       4.7    9.67E-05   0.0071
  Functional annotation cluster 10 enrichment score: 3.04                                           
   GO:0051092 positive regulation of NFκB transcription factor activity   7       6.6    1.77E-04   0.0092
   GO:0006954 inflammatory response                                       10      9.4    5.76E-04   0.0219
   UP_KEYWORDS innate immunity                                            7       6.6    0.0022     0.0150

NFκB, nuclear factor kappaB.

###### 

Functional Annotation Clustering Analysis of H~2~O~2~ ADSC-EV Proteome

  Term                                                        Count   \%     *P*        Benjamini *P*
  ----------------------------------------------------------- ------- ------ ---------- ---------------
  Functional annotation cluster 1 enrichment score: 9.33                                
   GO:0005615 extracellular space                             41      48.2   1.86E-23   1.21E-21
   GO:0005576 extracellular region                            37      43.5   7.46E-17   5.33E-15
   UP_KEYWORDS secreted                                       34      40     3.20E-13   6.90E-11
   UP_KEYWORDS signal                                         36      42.4   5.91E-06   1.42E-04
   UP_KEYWORDS glycoprotein                                   36      42.4   4.52E-05   6.50E-04
  Functional annotation cluster 2 enrichment score: 7.66                                
   UP_KEYWORDS heparin binding                                9       10.6   2.70E-09   2.92E-07
   GO:0030198 extracellular matrix organization               12      14.1   3.21E-09   7.93E-07
   GO:0008201\~heparin binding                                9       10.6   1.18E-06   1.37E-04
  Functional annotation cluster 3 enrichment score: 5.48                                
   UP_KEYWORDS extracellular matrix                           12      14.1   8.04E-09   5.79E-07
   GO:0030198 extracellular matrix organization               12      14.1   3.21E-09   7.93E-07
   GO:0001501 skeletal system development                     8       9.4    5.11E-06   4.73E-04
  Functional annotation cluster 4 enrichment score: 4.61                                
   GO:0018149 peptide cross-linking                           9       10.6   1.14E-10   4.24E-08
   GO:0030216 keratinocyte differentiation                    8       9.4    9.25E-08   1.71E-05
   GO:0008544 epidermis development                           7       8.2    3.89E-06   4.12E-04
  Functional annotation cluster 5 enrichment score: 4.3                                 
   GO:0010951 negative regulation of endopeptidase activity   12      14.1   1.79E-11   1.32E-08
   GO:0004867 serine-type endopeptidase inhibitor activity    7       8.2    8.14E-06   3.77E-04
  Functional annotation cluster 6 enrichment score: 3.55                                
   GO:0005178 integrin binding                                6       7.1    1.67E-04   0.0035
   GO:0005518 collagen binding                                5       5.9    2.15E-04   0.0041
   GO:0007155 cell adhesion                                   10      11.8   4.32E-04   0.0198
  Functional annotation cluster 7 enrichment score: 3.39                                
   GO:0098609 cell--cell adhesion                             8       9.4    3.85E-04   0.0202
  Functional annotation cluster 8 enrichment score: 3.06                                
   GO:0004866 endopeptidase inhibitor activity                7       8.2    3.95E-08   9.16E-06
   GO:0030449 regulation of complement activation             4       4.7    4.29E-04   0.0210
   UP_KEYWORDS inflammatory response                          5       5.9    0.0035     0.0276
  Functional annotation cluster 9 enrichment score: 2.80                                
   GO:0042744 hydrogen peroxide catabolic process             5       5.9    2.53E-06   3.13E-04
   GO:0000302 response to reactive oxygen species             4       4.7    9.36E-04   0.0400
  Functional annotation cluster 10 enrichment score: 2.14                               
   GO:0001501 skeletal system development                     8       9.4    5.11E-06   4.73E-04
   GO:0030199 collagen fibril organization                    4       4.7    9.36E-04   0.0400
   GO:0005788 endoplasmic reticulum lumen                     6       7.1    0.0019     0.0196

###### 

Functional Annotation Clustering Analysis of Proteins Unique to Control ADSC-EVs

  Term                                                     Count   \%     *P*        Benjamini *P*
  -------------------------------------------------------- ------- ------ ---------- ---------------
  Functional annotation cluster 1 enrichment score: 8.65                             
   GO:0005615 extracellular space                          23      59.0   7.32E-16   4.15E-14
   UP_KEYWORDS secreted                                    24      61.5   1.15E-14   1.60E-12
   GO:0005576 extracellular region                         23      59.0   3.17E-14   1.13E-12
   UP_KEYWORDS signal                                      21      53.8   9.27E-06   4.33E-04
   UP_KEYWORDS glycoprotein                                21      53.8   3.75E-05   0.0011
  Functional annotation cluster 2 enrichment score: 3.01                             
   GO:0006911 phagocytosis, engulfment                     5       12.8   1.11E-06   4.53E-04
   GO:0006910 phagocytosis, recognition                    4       10.3   3.37E-05   0.0046
   GO:0045087 innate immune response                       8       20.5   4.37E-05   0.0044
   UP_KEYWORDS immunoglobulin C region                     3       7.7    3.43E-04   0.0080
  Functional annotation cluster 3 enrichment score: 1.82                             
   GO:0005925 focal adhesion                               6       15.4   0.0012     0.0165
   GO:0005509 calcium ion binding                          7       18.0   0.0038     0.1011
  Functional annotation cluster 4 enrichment score: 1.56                             
   GO:0045087 innate immune response                       8       20.5   4.37E-05   0.0044
   UP_KEYWORDS innate immunity                             4       10.3   0.0123     0.1341
   UP_KEYWORDS inflammatory response                       3       7.7    0.0320     0.2237
  Functional annotation cluster 5 enrichment score: 1.28                             
   GO:0000502 proteasome complex                           3       7.7    0.0069     0.0718
   GO:0043488 regulation of mRNA stability                 3       7.7    0.0227     0.5135

###### 

Functional Annotation Clustering Analysis of Proteins Unique to H~2~O~2~ ADSC-EVs

  Term                                                           Count   \%     *P*        Benjamini *P*
  -------------------------------------------------------------- ------- ------ ---------- ---------------
  Functional annotation cluster 1 enrichment score: 1.75                                   
   GO:0008180 COP9 signalosome                                   3       16.7   4.79E-04   0.0088
   UP_KEYWORDS nucleotide binding                                6       33.3   0.0125     0.2309
   UP_KEYWORDS ATP binding                                       5       27.8   0.0243     0.3474
  Functional annotation cluster 2 enrichment score: 1.73                                   
   UP_KEYWORDS Ubl conjugation                                   6       33.3   0.0103     0.3019
   UP_KEYWORDS isopeptide bond                                   5       27.8   0.01218    0.2729
  Functional annotation cluster 3 enrichment score: 1.59                                   
   UP_KEYWORDS acetylation                                       10      55.6   6.51E-04   0.0654
   UP_KEYWORDS methylation                                       5       27.8   0.0080     0.3401
   UP_KEYWORDS Ubl conjugation                                   6       33.3   0.0103     0.3019
   GO:0098609 cell--cell adhesion                                3       16.7   0.0301     0.8627
   GO:0098641 cadherin binding involved in cell--cell adhesion   3       16.7   0.0338     0.8172
  Functional annotation cluster 4 enrichment score: 1.28                                   
   GO:0006413 translational initiation                           3       16.7   0.0083     0.5560
   GO:0044822 poly(A) RNA binding                                5       27.8   0.0235     0.9050
  Functional annotation cluster 5 enrichment score: 1.26                                   
   GO:0005576 extracellular region                               8       44.4   3.64E-04   0.0089
   GO:0005615 extracellular space                                6       33.3   0.0064     0.0905
   GO:0010951 negative regulation of endopeptidase activity      3       16.7   0.0065     0.7210

![Venn diagram illustrating common and unique proteins in control ADSC-EVs and H~2~O~2~ ADSC-EVs.](gox-7-e2588-g001){#F1}

Seventeen proteins identified in both groups that were altered \>2-fold in H~2~O~2~ ADSC-EVs are listed in Table [5](#T5){ref-type="table"}. Twelve (71%) of these proteins are involved in angiogenesis, and 8 (47%) have antimicrobial properties. Angiogenesis-promoting proteins enriched in H~2~O~2~ ADSC-EVs included transforming growth factor-beta-induced protein ig-h3, inter-alpha-trypsin inhibitor heavy chain H2, periostin, and pentraxin-related protein PTX3.^[@R26]--[@R30]^

###### 

Proteins Identified in Both Control ADSC-EVs and H~2~O~2~ ADSC-EVs that Were Altered (\>2-Fold Change) in H~2~O~2~ ADSC-EVs

  Proteins Upregulated in H~2~O~2~-ADSC-EVs               Abbreviation   MW (kDa)   UniProtKB Acc. \#\*   Fold Change   Function                                                                                             Reference
  ------------------------------------------------------- -------------- ---------- --------------------- ------------- ---------------------------------------------------------------------------------------------------- -----------
  Histone H4                                              H4_HUMAN       11         P62805                4.35          Major antimicrobial peptide on skin released from sebaceous glands                                   31
  Transforming growth factor-beta-induced protein ig-h3   BGH3_HUMAN     75         Q15582                3.59          Collagen-binding extracellular matrix protein; involved in vascular remodeling; pro-angiogenic       26
  Inter-alpha-trypsin inhibitor heavy chain H2            ITIH2_HUMAN    106        P19823                2.63          Serum protein that promotes hyaluronan-mediated angiogenesis in tissue injury                        27
  Filaggrin-2                                             FILA2_HUMAN    248        Q5D862                2.39          Essential for normal keratinocyte differentiation; C-terminal fragments are antimicrobial peptides   32, 33
  Periostin                                               POSTN_HUMAN    93         Q15063                2.39          Extracellular matrix protein that promotes angiogenesis and tissue repair                            28
  Thrombospondin-1                                        TSP1_HUMAN     129        P07996                2.32          Potent endogenous inhibitor of angiogenesis                                                          34
  Pentraxin-related protein PTX3                          PTX3_HUMAN     42         P26022                2.22          Pattern recognition molecule of innate immune system; promotes angiogenesis after stroke             29, 30
  Annexin A5                                              ANXA5_HUMAN    36         P08758                2.09          Inhibits tumor angiogenesis; probe for apoptosis                                                     35
  Proteins Downregulated in H~2~O~2~-ADSC-EVs             Abbreviation   MW (kDa)   UniProtKB Acc. \#     Fold Change   Function                                                                                             Reference
  Plakophilin-1                                           PKP1_HUMAN     83         Q13835                --5.56        Structural component of desmosomes important for cell--cell adhesion                                 36
  Vitamin D-binding protein                               VTDB_HUMAN     53         P02774                --2.65        Inhibits angiogenesis; antiendothelial activity                                                      37
  Apolipoprotein B-100                                    APOB_HUMAN     516        P04114                --2.65        Contains cryptic host defense peptides                                                               38
  Lactotransferrin                                        TRFL_HUMAN     78         P02788                --2.51        Inhibits angiogenesis in colon tumor model; iron-binding antimicrobial protein                       39, 40
  Serotransferrin                                         TRFE_HUMAN     77         P02787                --2.51        Inhibits angiogenesis in pancreatic tumor model; iron-binding antimicrobial protein                  41, 42
  Alpha-fetoprotein                                       FETA_HUMAN     69         P02771                --2.51        Modulates expression of VEGF; pro-angiogenic                                                         43
  Fatty acid-binding protein 5                            FABP5_HUMAN    15         Q01469                --2.09        Promotes angiogenesis and activates IL6/STAT3/VEGFA pathway                                          44
  Dermcidin                                               DCD_HUMAN      11         P81605                --2.09        Antimicrobial peptide                                                                                45
  Hornerin                                                HORN_HUMAN     282        Q86YZ3                --2.08        Protein in skin that contains cationic antimicrobial peptides; pro-angiogenic                        46, 47

\*UniProtKB Acc. \#, UniProt Knowledgebase Accession Number.

MiRNA Content of ADSC-EVs and H~2~O~2~ ADSC-EVs
-----------------------------------------------

A total of 495 and 454 known miRNAs were identified in control ADSC-EVs and H~2~O~2~ ADSC-EVs, respectively. Using a cutoff of \>2-fold change and *P* \< 0.01, 2 miRNAs were increased and 12 miRNAs (including 10 antiangiogenic miRNAs) were reduced in H~2~O~2~ ADSC-EVs (Table [6](#T6){ref-type="table"}). Evaluation of putative target mRNAs using TargetScan Release 7.2 identified 980 predicted gene targets of these differentially expressed miRNAs. Functional GO enrichment analysis of constructed gene sets in DAVID identified the most highly enriched biological processes as transcription from RNA polymerase II promoter and embryonic skeletal system morphogenesis (Table [7](#T7){ref-type="table"}).

###### 

Differentially Expressed miRNAs (\>2-Fold Change, *P* \< 0.01) in H~2~O~2~ ADSC-EVs Compared to Control ADSC-EVs

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  miRNA              Fold Change   Normalized Abundance\   Normalized Abundance H~2~O~2~ ADSC-EVs   *P*        Role in Angiogenesis             Reference
                                   Control ADSC-EVs                                                                                             
  ------------------ ------------- ----------------------- ---------------------------------------- ---------- -------------------------------- -----------
  hsa-miR-10395-5p   13.76         2.17                    29.86                                    0.0007     Unknown                          

  hsa-miR-10395-3p   13.56         2.17                    29.42                                    0.0008     Unknown                          

  hsa-miR-24-3p      --3.42        397.69                  116.12                                   \<0.0001   Antiangiogenic                   13

  hsa-miR-16-5p      --3.08        75.23                   24.44                                    0.0025     Antiangiogenic                   13

  hsa-miR-93-5p      --2.64        88.65                   33.53                                    0.0044     Pro-angiogenic                   48

  hsa-miR-31-5p      --2.56        509.43                  199.31                                   \<0.0001   Pro-angiogenic, antiangiogenic   49, 50

  hsa-miR-23a-3p     --2.46        441.80                  179.85                                   \<0.0001   Pro-angiogenic                   13

  hsa-miR-152-3p     --2.27        156.95                  69.07                                    0.0011     Antiangiogenic                   51

  hsa-miR-122-5p     --2.23        894.20                  401.27                                   \<0.0001   Antiangiogenic                   52

  hsa-miR-134-5p     --2.19        223.78                  102.32                                   0.0064     Antiangiogenic                   53

  hsa-miR-221-3p     --2.19        12206.98                5582.17                                  \<0.0001   Antiangiogenic                   13

  hsa-miR-196a-5p    --2.17        173.55                  79.87                                    0.0063     Antiangiogenic                   54

  hsa-miR-23b-3p     --2.11        255.23                  120.97                                   0.0005     Antiangiogenic                   55

  hsa-miR-222-3p     --2.11        871.46                  413.91                                   \<0.0001   Antiangiogenic                   13
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Biological Processes Enriched among the Genes Predicted to Be Targeted by miRNAs that Were Downregulated (\>2-Fold Change, *P* \< 0.01) in H~2~O~2~ ADSC-EVs Compared to Control ADSC-EVs

  GO Term                                                          Count   \%    *P*        Benjamini *P*
  ---------------------------------------------------------------- ------- ----- ---------- ---------------
  GO:0006366 transcription from RNA polymerase II promoter         53      5.4   2.75E-06   0.0092
  GO:0048704 embryonic skeletal system morphogenesis               12      1.2   2.95E-06   0.0050
  GO:0045893 positive regulation of transcription, DNA templated   52      5.3   6.66E-06   0.0075
  GO:0009952 anterior/posterior pattern specification              16      1.6   1.28E-05   0.0108
  GO:1900740 positive regulation of protein insertion into                                  
  Mitochondrial membrane involved in apoptotic signaling pathway   10      1.0   1.36E-05   0.0092
  GO:0014911 positive regulation of smooth muscle cell migration   8       0.8   4.15E-05   0.0232
  GO:0008284 positive regulation of cell proliferation             46      4.7   4.27E-05   0.0205
  GO:0048863 stem cell differentiation                             9       0.9   4.58E-05   0.0192
  GO:0045944 positive regulation of transcription from RNA                                  
  Polymerase II promoter                                           80      8.2   5.72E-05   0.0213
  GO:0030335 positive regulation of cell migration                 24      2.4   8.03E-05   0.0269
  GO:0000122 negative regulation of transcription from RNA                                  
  Polymerase II promoter                                           62      6.3   1.01E-04   0.0307
  GO:0006468 protein phosphorylation                               44      4.5   1.08E-04   0.0300

Flap Survival and Capillary Density
-----------------------------------

On postoperative day 7, survival area was significantly larger in skin flaps of mice treated with H~2~O~2~ ADSC-EVs compared with vehicle (*P* = 0.04, ANOVA; Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Increased capillary density was observed in the H~2~O~2~ ADSC-EV group compared to that in the other groups (*P* \< 0.001, ANOVA; Figs. [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). Increased vessel diameter was also apparent in tissues treated with H~2~O~2~ ADSC-EVs (Fig. [5](#F5){ref-type="fig"}).

![Quantitative analysis of skin flap survival area. \**P* \< 0.05 vs vehicle.](gox-7-e2588-g002){#F2}

![Representative images of skin flaps injected with vehicle (A), control ADSC-EVs (B), and H2O2 ADSC-EVs (C) (elevated to display the underside) on postoperative day 7. Note the increased area of viable tissue within the flap treated with H~2~O~2~ ADSC-EVs (C).](gox-7-e2588-g003){#F3}

![Quantitative analysis of capillary density. \**P* \< 0.05 vs vehicle and control ADSC-EVs.](gox-7-e2588-g004){#F4}

![Representative hematoxylin--eosin-stained sections of skin flaps injected with vehicle (A), control ADSC-EVs (B), and H~2~O~2~ ADSC-EVs (C). Top panels are magnified views of corresponding boxes in bottom panels. Scale bar = 50 µm. Blood vessels are denoted by \*.](gox-7-e2588-g005){#F5}

DISCUSSION
==========

The use of stem cell-derived EVs has gained much attention as an emerging approach for therapeutic angiogenesis in ischemic diseases.^[@R14]^ In fact, EVs are currently being tested in clinical trials in patients with acute ischemic stroke, type 1 diabetes mellitus, and macular holes.^[@R8]^ Recently, Bai et al determined that preconditioning ADSCs with a low concentration of H~2~O~2~ improved the pro-angiogenic properties of secreted EVs in vitro and in vivo in a model of skin flap transplantation, suggesting that H~2~O~2~ may induce EVs to exhibit an enhanced pro-angiogenic capacity for cell-free therapeutic applications.^[@R7]^ In this study, comprehensive proteomic and miRNA analyses revealed that exposure to an H~2~O~2~-induced oxidative stress microenvironment altered the expression of several angiogenic and antimicrobial proteins and miRNAs in ADSC-EVs. We also verified that H~2~O~2~ ADSC-EVs increased microvascular density and viability of random pattern skin flaps in vivo.

Functional enrichment analysis of proteins found only in H~2~O~2~ ADSC-EVs identified COP9 signalosome as the primary enriched GO term unique to H~2~O~2~ ADSC-EVs. The COP9 signalosome is a highly conserved multimeric protein complex with kinase activity that cooperates with the ubiquitin/26S proteasome system in the regulation of stability of important cellular proteins.^[@R25]^ The COP9 signalosome has been shown to direct the production of vascular endothelial growth factor, a major mediator of angiogenesis, through c-Jun signaling in tumor cells, thereby promoting angiogenesis.^[@R25]^ Upregulation of proteins involved in this complex therefore may be 1 mechanism by which H~2~O~2~ ADSC-EVs enhance angiogenesis.

Angiogenesis is well known to be a complex process that is regulated by a variety of angiogenic stimulators and inhibitors.^[@R13]^ H~2~O~2~ pretreatment resulted in the upregulation and downregulation of several pro-angiogenic and antiangiogenic proteins and miRNAs (listed in Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}), thereby influencing this intricate balance. Angiogenesis-promoting proteins enriched in ADSC-EVs after H~2~O~2~ stimulation included the extracellular matrix proteins periostin and transforming growth factor-beta-induced protein ig-h3, and pentraxin-related protein PTX3 and inter-alpha-trypsin inhibitor heavy chain H2, previously shown to promote wound healing and vascular remodeling.^[@R26]--[@R30]^ Of the 14 differentially expressed miRNAs, 10 are considered to be antiangiogenic and all were downregulated in H~2~O~2~ ADSC-EVs, consequently increasing angiogenesis via release of inhibition.^[@R13],[@R50]--[@R55]^ Both groups contained known pro-angiogenic miRNAs that were not differentially expressed such as abundant levels of miR-21. MiR-21 has been shown to have antibacterial, antiinflammatory, and proliferative roles in a diabetic infected wound model and has been proposed as a promising intervention target for the treatment of refractory wounds such as diabetic foot ulcers.^[@R56]^

Results from this study also suggest that ADSC-EVs may benefit wound healing and infection prevention of skin flaps through their antimicrobial peptide content. Twenty-four antimicrobial peptides and proteins important in innate immunity were identified in ADSC-EVs, including dermcidin, lipocalin-1, lysozyme C, neutrophil defensin 1, prolactin-inducible protein, psoriasin (S100A7), calprotectin (S100A8/A9), histone H4, lactotransferrin, and hornerin, to name a few. These peptides are known to have activities against various Gram-positive and Gram-negative bacteria, viruses, and fungi, and likely are responsible for the antimicrobial properties of MSCs observed by us and others.^[@R57],[@R58]^ Some of these peptides have been identified in sweat EVs, suggesting a role in skin immunity.^[@R59]^ Although it has been postulated that MSC-EVs contain active agents with potential antimicrobial effects, a paucity of data exists regarding the antimicrobial peptide cargo of ADSC-EVs and how it may be affected by different microenvironments.^[@R60]^ In general, antimicrobial peptides and proteins were reduced in H~2~O~2~ ADSC-EVs. However, histone H4 and filaggrin-2, whose peptides are important in antimicrobial defense of the skin, were upregulated in H~2~O~2~ ADSC-EVs.^[@R31]--[@R33]^ Interestingly, pentraxin-related protein PTX3, which was also upregulated in H~2~O~2~ ADSC-EVs, is an essential soluble pattern recognition molecule of the innate immune system and a key regulator of angiogenesis that exerts dual functions involving both antimicrobial resistance and tissue repair.^[@R29],[@R30]^

Although the therapeutic benefits of EVs seem highly encouraging in preclinical models, technical challenges currently exist in this exciting new field that must be resolved before EV-based therapeutics may be incorporated into clinical practice. One of the major challenges is the efficient production of EVs in a clinically applicable scale. Other obstacles include a lack of consensus (1) on the best method to isolate and purify EVs, (2) on the compositions of EVs from different sources or different culture conditions, and (3) as to how to quantitate the EVs.^[@R61]^ Nevertheless, Mendt et al in conjunction with Codiak Biosciences have recently developed a process for the production of Good Manufacturing Practice-grade EVs derived from MSCs.^[@R62]^ Using a Quantum bioreactor culture system, they demonstrated successful Good Manufacturing Practice-grade production, scalability, EV stability, and consistent in vitro and in vivo efficacy in preclinical models of pancreatic cancer.^[@R62]^ In addition, EVs can be lyophilized and stored at 4°C without compromising stability for 36 months and are easily reconstituted, thereby demonstrating great promise as an "off-the-shelf" therapeutic.

CONCLUSIONS
===========

ADSC-EVs hold immense potential as an allogeneic, "off-the-shelf" cell-free therapeutic for skin flap transplantation offering the benefits of stem cell therapy while representing a theoretically safer alternative. The broad repertoire of angiogenic and antimicrobial proteins and miRNAs in ADSC-EVs, which are altered after H~2~O~2~ preconditioning, likely contributes to their favorable therapeutic effects observed on skin flap survival. Further investigation is needed to determine the relative importance of particular miRNAs and proteins and their affected signaling pathways in flap recovery.
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